TITLE

News you can use

PUB. DATE
June 2010
SOURCE
Pharmacy Today;Jun2010, Vol. 16 Issue 6, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article offers news briefs related to the pharmaceutical industry in the U.S. A study shows that diabetic women who consume 35% of bran are less likely to die from cardiovascular disease and 28% less likely to die from any cause. Nominations for the 2010 Commitment to Alzheimer's, Recognition of Excellence (CARE) Pharmacy Award are opened. The U.S. Food and Drug Administration (FDA) has ended its enforcement discretion for unapproved pancreatic enzyme products (PEPs) on April 28, 2010.
ACCESSION #
51639098

 

Related Articles

  • End of Unapproved Pancreatic Enzymes Ensures Safety: CFF. Young, Donna // BioWorld Today;5/3/2010, Vol. 21 Issue 84, p4 

    The article reports that the U.S. Food and Drug Administration (FDA) issued a rule ordering manufacturers of unapproved pancreatic enzyme products (PEPs) to stop manufacturing and distributing their products in the U.S. According to Preston Campbell, executive vice president for medical affairs...

  • Pipeline 2011. Perry, Leah E. // Drug Topics;Jan2011, Vol. 155 Issue 1, p30 

    The article offers forecasts on the trends in the pharmaceutical industry for 2011 in the U.S. It reveals that drug development has continued to drop compared to the successful period in previous years. It also shows the slow-moving rate at which the Food and Drug Administration (FDA) approves...

  • Pharmaceutical Business Environment Ratings.  // U.S. Pharma & Healthcare Report;Q2 2009, p9 

    The article reports on the Business Environment Rankings for the U.S. for the second quarter of 2009, particularly for the pharmaceutical industry. It is noted that closes competitor of the U.S. in the said industry is Puerto Rico. It is asserted that new products are evaluated by the Food and...

  • Pipeline.  // Medical Marketing & Media;Aug2011, Vol. 46 Issue 8, p11 

    The article offers news briefs related to pharmaceutical industry in the U.S. including the approval issued by the Food and Drug Administration (FDA) for AztraZeneca's Brilinta, the marketing of nasal vaccine FluMist from MedImmune and the approval of Boostrix for the prevention of whooping cough.

  • FDA Publishes Revised Process-Validation Guidance. Greb, Erik // BioPharm International;Feb2011, Vol. 24 Issue 2, p10 

    The article reports on the publication of a revised process-validation guidance by the U.S. Food and Drug Administration (FDA). It notes that the revised document explains the components of process validation for the manufacture of human and animal drug and biological products. It also mentions...

  • Three issues that will define 2011. DEARMENT, ALARIC // Drug Store News;2/7/2011, Vol. 33 Issue 2, p27 

    The article examines the issues faced by the generic drug industry in the U.S. It notes that drug approval is challenging due to the strength of the Food and Drug Administration's (FDA) regulatory system. It further states that the backlog of applications at the FDA's Office of Generic Drugs...

  • Excess Marks the Spot.  // Time;9/27/1982, Vol. 120 Issue 13, p87 

    The article reports on the claim of the U.S. Food and Drug Administration (FDA) about the increasing number of people and organization which abuse drug use. It states that the claim was announced after the FDA found out that only three drugs out of 96 received approval in 1981. The article also...

  • FDA Drug Approval to Change its Ways? Elliott, William T. // Clinical Oncology Alert;May2008 Pharmacology Watch, p1 

    The article reports that the drug approval process adopted by the U.S. Food and Drug Administration (FDA) has come under scrutiny based on the number of drug withdrawals and black box warnings in the last 10 years. The criticisms have been focused on the Prescription Drug User Fee Act (PDUFA)...

  • FDA Drug Approval to Change its Ways?  // Travel Medicine Advisor;May2008, Vol. 18 Issue 5, p1 

    The article deals with the issue on whether the drug approval process implemented by the U.S. Food and Drug Administration (FDA) should be changed. It is cited that the Prescription Drug Use Fee Act (PDUFA) enacted in 1992, which transformed the drug approval process of the FDA, is under...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics